In 2023, the National Comprehensive Cancer Network<sup>®</sup> (NCCN<sup>®</sup>) updated its guidelines for managing breast cancer risk in patients with a <i>CHEK2</i> p.I157T variant, recommending de-escalation of enhanced screening based on this variant alone. This evidence concerns the gene CHEK2 and breast cancer.